Cell Genesys, Inc. - Price Analysis Snapshot

This Report features up to a ten-year record of the equity Price history for Cell Genesys, Inc.. Tabular results include the High, Low and Closing price for the quarter. There is also a calculation of percentage change in price for both Quarterly and Annual periods. Price values are adjusted for stock splits and dividends.

Cell Genesys, Inc.. The Group's principal activities are researching, developing and commercializing novel biological therapies for patients with cancer. It currently has three product platforms: GVAX cancer vaccines, oncolytic virus therapies and cancer gene therapies. The Group conducts clinical trials in multiple types of cancer utilizing its GVAX cancer vaccines and oncolytic virus therapy product platforms. GVAX vaccines consist of irradiated tumor cells, genetically modified to secrete a hormone that stimulates the body's immune response to vaccines. Oncolytic virus therapies which employ genetically modified adenoviruses are engineered to selectively replicate in and kill cancer cells.

Not the Report you are looking for? Click here for more browsing options.

view sample Single Report

view sample All Basic Reports

Layout and Content of a Typical Report